Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the
safety and effectiveness of this new drug with the standard way of treatment of deep vein
thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new
events of thrombosis and pulmonary embolism and bleeding risk.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatments:
Factor Xa Inhibitors Heparin Rivaroxaban Vitamin K Vitamins